iBio enters ATM equity facility for up to $7.35M in common stock sales

iBio, Inc.

Entry into ATM Agreement with Chardan Capital Markets and Craig-Hallum Capital Group for at-the-market offerings.
Aggregate market value of shares eligible for sale under the ATM prospectus supplement is $7,350,000.
Sales agents receive fixed commission rate of up to 3.0% of gross proceeds.
Shelf registration statement on Form S-3 filed on July 3, 2024, must be effective before sales can occur.
Company has no obligation to sell shares and may suspend offerings at any time.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.